Key Points
- Director Musa Tariq sold 116 shares on Nov. 19 at an average price of $96.25 for $11,165, reducing his stake to 7,859 shares (a 1.45% decrease) after similar sales in September and October.
- Recent performance and results: GH recently traded near $106.96 (one-year high $110), has a market cap of $13.48B and a negative P/E (-33.39), and reported Q3 EPS of -$0.39 beating estimates with revenue up 38.5% year-over-year.
- Strong institutional interest: Major investors including Baillie Gifford, Invesco, Franklin and ARK have materially increased positions and institutional holders own about 92.6% of the stock; analysts’ consensus is a "Moderate Buy" with an average target of $77.14.
Guardant Health, Inc. (NASDAQ:GH - Get Free Report) Director Musa Tariq sold 116 shares of the stock in a transaction dated Wednesday, November 19th. The shares were sold at an average price of $96.25, for a total value of $11,165.00. Following the transaction, the director owned 7,859 shares in the company, valued at $756,428.75. This trade represents a 1.45% decrease in their ownership of the stock. The sale was disclosed in a legal filing with the SEC, which is available at this hyperlink.
Musa Tariq also recently made the following trade(s):
- On Friday, October 17th, Musa Tariq sold 116 shares of Guardant Health stock. The stock was sold at an average price of $66.95, for a total value of $7,766.20.
- On Wednesday, September 17th, Musa Tariq sold 116 shares of Guardant Health stock. The stock was sold at an average price of $55.63, for a total transaction of $6,453.08.
Guardant Health Stock Performance
Shares of GH stock traded up $6.66 on Friday, hitting $106.96. 1,006,505 shares of the company's stock traded hands, compared to its average volume of 2,477,703. Guardant Health, Inc. has a one year low of $29.91 and a one year high of $110.00. The company's fifty day simple moving average is $73.93 and its 200 day simple moving average is $58.08. The stock has a market capitalization of $13.48 billion, a price-to-earnings ratio of -33.39 and a beta of 1.56.
Guardant Health (NASDAQ:GH - Get Free Report) last posted its quarterly earnings results on Wednesday, October 29th. The company reported ($0.39) earnings per share for the quarter, topping the consensus estimate of ($0.48) by $0.09. During the same quarter in the prior year, the company earned ($0.88) earnings per share. Guardant Health's revenue was up 38.5% compared to the same quarter last year. Guardant Health has set its FY 2025 guidance at EPS. As a group, sell-side analysts anticipate that Guardant Health, Inc. will post -2.9 earnings per share for the current fiscal year.
Institutional Inflows and Outflows
Institutional investors and hedge funds have recently made changes to their positions in the company. Baillie Gifford & Co. grew its stake in Guardant Health by 6.6% in the third quarter. Baillie Gifford & Co. now owns 5,127,692 shares of the company's stock worth $320,378,000 after purchasing an additional 317,906 shares during the period. Invesco Ltd. boosted its holdings in shares of Guardant Health by 27.3% during the 2nd quarter. Invesco Ltd. now owns 3,558,501 shares of the company's stock valued at $185,184,000 after buying an additional 763,834 shares in the last quarter. Franklin Resources Inc. grew its position in shares of Guardant Health by 26.1% in the 3rd quarter. Franklin Resources Inc. now owns 2,926,315 shares of the company's stock worth $182,836,000 after buying an additional 606,368 shares during the period. Geode Capital Management LLC increased its stake in shares of Guardant Health by 0.5% in the 2nd quarter. Geode Capital Management LLC now owns 2,920,714 shares of the company's stock worth $152,014,000 after acquiring an additional 13,088 shares in the last quarter. Finally, ARK Investment Management LLC increased its stake in shares of Guardant Health by 100.4% in the 2nd quarter. ARK Investment Management LLC now owns 2,823,497 shares of the company's stock worth $146,935,000 after acquiring an additional 1,414,381 shares in the last quarter. Hedge funds and other institutional investors own 92.60% of the company's stock.
Wall Street Analyst Weigh In
Several analysts have weighed in on the company. Canaccord Genuity Group set a $100.00 price objective on Guardant Health in a research report on Thursday, October 30th. Barclays lifted their target price on shares of Guardant Health from $70.00 to $85.00 and gave the stock an "overweight" rating in a research note on Thursday, October 30th. Raymond James Financial increased their price target on shares of Guardant Health from $59.00 to $61.00 and gave the company an "outperform" rating in a research report on Thursday, July 31st. Weiss Ratings restated a "sell (d-)" rating on shares of Guardant Health in a research report on Wednesday, October 8th. Finally, Guggenheim increased their target price on shares of Guardant Health from $56.00 to $67.00 and gave the stock a "buy" rating in a report on Thursday, September 25th. Twenty-three research analysts have rated the stock with a Buy rating and one has assigned a Sell rating to the stock. According to MarketBeat, the company currently has a consensus rating of "Moderate Buy" and an average target price of $77.14.
Get Our Latest Stock Report on GH
About Guardant Health
(
Get Free Report)
Guardant Health, Inc, a precision oncology company, provides blood and tissue tests, data sets, and analytics in the United States and internationally. The company provides Guardant360; Guardant360 LDT; Guardant360 CDx Test; Guardant360 Response Test; Guardant360 TissueNext Test; GuardantINFINITY Test; GuardantConnect, an integrated software-based solution designed for clinical and biopharmaceutical customers to connect patients tested with assays with actionable alterations with potentially relevant clinical studies; GuardantOMNI Test for advanced stage cancer; and GuardantINFORM, an in-silico research platform for tumor evolution and treatment resistance across various biomarker-driven cancers.
Recommended Stories
This instant news alert was generated by narrative science technology and financial data from InsiderTrades.com in order to provide readers with the fastest and most accurate reporting. Please send any questions or comments about this story to [email protected].
